





19th CardioVascular Summit: TCTAP 2014generation DES with long term outcomes. Our objective is to compare the efﬁcacy and
safety of the XIENCE V EES and the MULTI-LINK VISION cobalt chromium
stent (CCS) which has same platform in the setting of primary intervention for STEMI
patients.
Methods: Consecutive 338 patients with STEMI, who were treated with EES (162
patients) and CCS (176 patients). Within ten months angiographic follow-up results
and 2-year clinical follow-up outcomes were compared between 2 groups.
Results: The prevalence of diabetes and Chronic kidney disease were higher, the stent
length was longer (24.19.5 vs. 18.28.3, p<0.05), and late loss was smaller in EES
than in CCS group (0.250.24 vs. 0.550.33). However, the initial success rate was
similar between two groups. Follow-up data for 2-year, % binary restenosis (2.0 vs.
10.9%, p<0.05), TLR (2.0% vs. 9.7%, p<0.05), MI ( 0.7% vs.4.8%, p<0.05) and
stent thrombosis (0.7% vs. 4.2%, p<0.05) were signiﬁcantly higher in CCS than in
EES group.
Conclusion: EES implantation in patients with STEMI cases inhibited 2-year MACE
including TLR, MI and ST without increasing mortality compared with CCS
implantation.
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Background: Primary PCI in STEMI is the preferred treatment, but not a feasible
option for many and pharmacoinvasive therapy might be a practical solution in the
Indian context. The objective of this study is to assess the efﬁcacy of pharma-
coinvasive strategy in STEMI patients versus primary PCI.
Methods: This is an observational, multicenter study that prospectively enrolled 200
patients with STEMI. Patients who were ﬁbrinolysed (n¼45) formed arm ‘A’ and
underwent CAG within 3-24 hours with coronary intervention as appropriate. Arm ‘B’
consisted of patients who opted for primary PCI (n¼155). Primary endpoint was
composite of death, cardiogenic shock, reinfarction, repeat revascularization or
congestive heart failure up to 1 year.
Results: The IRA patency at angiogram was 82.2% in arm A and 22.6% in arm B
(‘p’ <0.001). PCI was performed in 73.3% Vs 100 % (‘p’<0.001), thrombus was
present in 26.7% Vs 63.2% (‘p’<0.001) in arms A & B respectively. Signiﬁcantly
more number of patients in arm A had TIMI 3 ﬂow in the culprit vessel at angio-
gram than arm B, 27.9% Vs 4.5% (‘p’ < 0.001). Failed ﬁbrinolysis occurred in
12.1%. Total ischemic time was 245 minutes (185-395) for arm A and 260 minutes
(185-390) for arm B. There was no difference in bleeding risk. Primary end
point occurred in 13.3% in arm A and in 9% in arm B, ‘p’¼ 0.40, (RR 0.64; 95% CI
0.24- 1.79).
Conclusion: Pharmacoinvasive strategy resulted in comparable outcomes as primary
PCI at 1 year. Larger RCTs are required to conﬁrm these ﬁndings.
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Background: During the last decades, as the treatment for acute myocardial infarction
(AMI) has been improved, in-hospital mortality of AMI has been decreased.
Accordingly, the purpose of this study was to ensure and reassess the importance of
Killip classiﬁcation in modern pharmaco-invasive treatment eracompared with other
common prognostic variables.
Methods: From January 2013 to July 2013, we analyzed information from 250 patients
with AMI in Mie CCU registry data. Mie CCU network was established for the early
pre-hospital care of patients with AMI and consecutive AMI patients was registered at
Mie CCU registry data. They were categorized to Killip 1, 2/3 (heart failure) and 4
(shock status). Multivariate cox proportional hazard models were developed to
determine the prognostic importance of killip classiﬁcation in comparison with other
variables. Primary end point of this study is deﬁned as all cause in-hospital mortality.
Results: Overall in-hospital mortality was 11.4%. Higher Killip classiﬁcation was
associated with higher in-hospital mortality (2.1% in Killip 1, 6.8% in 2/3, 45.9% in 4;
P<0.0001, See ﬁgure). According to the multivariate analysis, Killip classiﬁcation,
serum-creatinine and postrprocedural TIMI ﬂow were independent predictor for in-
hospital mortality. In addition, Killip classiﬁcation is the strongest independent pre-
dictor with hazard ratio of 7.3 compared to other factors.
Conclusion: Killip classiﬁcation is still powerful independent predictor for in-hospital
mortality. In comparison with the studies for the last several decades, in-hospital
mortality in patients with Killip 1 and 2/3 at modern treatment era was lower.S4 JACC Vol 63/12/Suppl S j April 22–25, 2014 jTCTAP A-012
The Protective Effect of Aspiration Thrombectomy on Side Branch Compromise
and Twelve Months Clinical Outcomes in AMI with Bifurcation Lesion
Undergoing Primary PCI
Ji Young Park, Jigyoung Park, Sungkee Rhy, Changsup Song
Eulji General Hospital, Seoul, Korea (Republic of)
Background: Bifurcation lesions (BF) remains a challenging lesion subset, often
associated with lower success rates. Side branch (SB) compromise in bifurcation
lesion is a major determinant of lower procedural success rates and adverse outcomes.
Aspiration thrombectomy (AT) prevent distal embolization in acute myocardial
infarction (AMI). The aim of this study is to evaluate the protective effect of AT on SB
compromise in BF lesions and twelve months clinical outcomes in AMI patients
undergoing primary percutaneous coronary intervention (PCI).
Methods: A total of 201 AMI patients with bifurcation lesion undergoing PCI were
analyzed between 2007 and 2011. The patients were divided into two groups ac-
cording to use of AT (AT group: n¼74, non AT group:n¼127).
We compared Thrombolysis In Myocardial Infarction (TIMI) of main and side
branch and 12 months clinical outcomes including mortality, reinfarction, target lesion
revascularization (TLR), and major adverse cardiac event (MACE) including mor-
tality, reinfarction, and TLR.
Results: Baseline clinical characteristics were similar between two groups. Angio-
graphic characteristics showed that LAD lesion was higher in non AT group (39.2%
vs 54.8%, p¼0.04) and RCA lesion was higher in AT group (45.9% vs 31.7%,
p¼0.050). Visible thrombus (94.6% vs 65.3%, p<0.001) and the use of GP IIb/IIIa
inhibitor (43.2% vs 27.6%, p¼0.030) was higher in AT group. PreTIMI was similar
between two groups. However, post TIMI 3 ﬂow was higher in AT group (94.4% vs
80.2%, p¼0.033). However, there were no difference of 12 months clinical outcomes
including mortality (5.4% vs 9.1%, p¼0.708), reinfarction (5.4% vs 12.1%, p¼0.324),
TLR (0.0% VS 3.0%, P¼535), and MACE (13.5% vs 28.8%, p¼0.093). Kaplan-
Meyer curve showed that the cumulative incidence of MACE was similar between two
groups (Log rank¼0.196)
Conclusion: In the present study, AT is related to post TIMI 3 ﬂow in AMI patients
with BF lesion undergoing primary PCI. However, cumulative incidence of MACE
was similar between two groups.TCTAP A-013
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Background: The presence of bundle branch block (BBB) has been associated with
poor clinical outcome in patients with acute myocardial infarction (MI). BBB,
particularly left BBB, in diabetes mellitus (DM) may signify advanced cardiovascularTCTAP Abstracts/ORAL/Acute Coronary Syndrome: STEMI, NSTE-ACS
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19th CardioVascular Summit: TCTAP 2014disease and worse left ventricular dysfunction. Prognostic implications of BBB in
diabetic patients with acute MI have yet to be clariﬁed.
Methods: We analyzed 23,724 patients with acute MI from the Korea Acute
Myocardial Infarction Registry and the Korea Working Group on Myocardial
Infarction Registry. Twelve-month clinical outcome was compared between patients
with BBB and those without BBB according to the presence of DM.
Results: Patients with left BBB (n ¼ 181) were older, more likely to be men, have
hypertension, DM, multi-vessel disease, left ventricular dysfunction, less likely to
have chest pain at presentation and receive percutaneous coronary intervention (PCI)
(67% vs. 86%) and beta blockers. In-hospital mortality was not different between
patients with left BBB and those without left BBB (0.6% vs. 0.5%). However, all-
cause mortality and the rate of major adverse cardiac events (MACE: all-cause
mortality, MI, and repeat revascularization) were higher in patients with left BBB at 1
month (6.6% vs. 1.8%, p < 0.001 and 11.6% vs. 5.9%, p ¼ 0.001) and 12 months
(11.6% vs. 3.7%, p < 0.001 and 27.6% vs. 19.3%, p ¼ 0.005), respectively. Patients
with right BBB (n ¼ 494) were older, more likely to be men, have prior stroke, less
likely to have chest pain at presentation and PCI (81% vs. 86%). In-hospital mortality
was not different between patients with right BBB and those without right BBB (0.4%
vs. 0.5%). All-cause mortality and MACE were similar at 1 month (2.2% vs. 1.8% and
6.5% vs. 5.9%), but higher in patients with right BBB at 12 months (6.3% vs. 3.7%,
p ¼ 0.003) and (22.7% vs. 19.3%, p ¼ 0.035). Diabetics with left BBB, compared to
diabetics without left BBB, had higher prevalence of multi-vessel disease (80% vs.
65%, p ¼ 0.024), which was similar in non-diabetics regardless of the presence of left
BBB. On multivariate analysis, left BBB was associated with 12-month all-cause
mortality in diabetics (hazard ratio: 2.6; 95% conﬁdence interval: 1.25 to 5.25;
p ¼ 0.010), but not in non-diabetics, while right BBB was not an independent
predictor of death regardless of diabetic status.
Conclusion: In patients with acute MI, BBB was associated with worse 12-month
clinical outcome. Particularly in diabetics, left BBB was associated with more
extensive coronary artery disease and higher mortality.
TCTAP A-014
Correlation Between the Age of Thrombus and Short Term Clinical Outcomes
in Patients Undergoing Primary Percutaneous Coronary Intervention
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Background: There is some data that plaque instability precedes the onset of
symptoms in acute myocardial infarction. But it is not known whether the age of
thrombus has any relation to short term clinical outcomes in patients treated with
thrombus aspiration during primary percutaneous coronary intervention (PPCI).
Methods: Consecutive patients of ST elevation myocardial infarction (STEMI) un-
dergoing PPCI with thrombus aspiration were included in the present study. After
passing the wire in the culprit artery, thrombus aspiration was done with a suction
catheter and the material was sent to histopathology lab in 10% formalin. It was
processed and the microscopic sections were categorised into old and fresh thrombus,
according to the existing guidelines. 30 day major adverse cardiac events (MACE)
deﬁned as a composite of death, myocardial infarction (MI) and revascularisation was
correlated with age of the thrombus, after adjusting for confounding factors.
Results: Baseline characteristics like age, sex, presence of risk factors and background
statin therapy were similar between the two groups. Of the total number of 79 patients
who presented within 6 hours of symptom onset, the aspirated material was insufﬁ-
cient in 7 patients. Out of the remaining 72 thrombi aspirated 40 (55.6%) showed lytic
changes and were classiﬁed as old. The rest 32 (44.4%) thrombi belonged to the fresh
category with intact leukocytes and ﬁbrin. There was no MACE at 30 days in either of
the categories.
Conclusion: In patients of STEMI undergoing PPCI short term clinical outcomes are
excellent irrespective of the age of the thrombus. However this study needs further
evaluation in a larger population with long term follow up.
TCTAP A-015
Required Multiple Aspiration Is the Sign of High Risk of Distal Embolization
in Acute Myocardial Infarction
Koshi Matsuo, Yasunori Ueda, Ryuta Sugihara
Osaka Police Hospital, Osaka, Japan
Background: Slow-ﬂow/no re-ﬂow phenomenon is mainly induced by distal embo-
lization of thrombus and necrotic core during PCI of AMI, and is associated with
unfavorable long-term clinical outcomes. Firstly, we perform aspiration thrombec-
tomy for AMI patients, but we will sometimes experience slow ﬂow or no re-ﬂow
phenomenon during coronary intervention. However, the high risk patients of distal
embolization are not well understood. Various imaging modalities have failed to
detect high risk patients of distal embolization for whom distal protection might be
beneﬁcial. We examined if the patients who require multiple aspiration to achieve
TIMI III ﬂow are high risk of patients of distal embolization.
Methods: Consecutive patients with AMI (n¼135) who received PCI with ﬁlter-
type distal protection device (Filtrap) were prospectively included. We classiﬁed
them into two groups by numbers of aspirations required to achieve TIMI III
coronary ﬂow: single aspiration (Group A, n¼92) and multiple aspiration (GroupJACC Vol 63/12/Suppl S j April 22–25, 2014 j TCTAP Abstracts/ORAB, n¼43). We compared between the groups the frequency of ﬁlter slow ﬂow or no
re-ﬂow phenomenon and of distal embolization captured by ﬁlter device. Distal
embolization was evaluated by the pathological examination of collected material
in the ﬁlter device.
Results: Although the distal embolization of thrombus was not deferent between
the groups (100% vs. 96%, P¼0.16), that of plaque debris was more frequent in
Group B than in Group A (95% vs. 18%, P<0.0001). Filter slow ﬂow/ no-reﬂow
phenomenon also occurred more frequently in Group B than in Group A (95% vs.
18%, P<0.0001).
Conclusion: Requirement of multiple aspirations to achieve TIMI III coronary ﬂow
was associated with high frequency of distal embolization and of ﬁlter slow ﬂow/
no-reﬂow.
TCTAP A-016
The Impact of First- Versus Second-generation Drug-eluting Stent on 1-year
Outcomes in Patients with ST-segment Elevation Myocardial Infarction
Undergoing Primary Coronary Intervention
Pyung Chun Oh, Woong Chol Kang, Jong Goo Seo, Soon Yong Suh,
Kyounghoon Lee, Seung Hwan Han, Taehoon Ahn, Eak Kyun Shin
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Background: The aim of the study was to compare the efﬁcacy and safety of second-
generation drug-eluting stent (DES) with ﬁrst-generation DES in primary percuta-
neous coronary intervention (PCI) for ST-segment elevation myocardial infarction
(STEMI).
Methods: A total of 1022 patients with STEMI undergoing primary PCI were
enrolled from the Korean Multicenter Endeavor (KOMER) trial (Cypher, n¼201;
Taxus, n¼204; Endeavor-Sprint, n¼204), the Gil PCI registry (XienceV, n¼85;
Endeavor-Resolute, n¼76), and the Korean Nobori registry (Nobori, n¼252). We
excluded the patients who had been cardiogenic shock at admission, received
thrombolytic therapy or had no follow-up data at 1 year. Major adverse cardiac
event (MACE), deﬁned as the composite of cardiac death, recurrent myocardial
infarction (MI), or target lesion revascularization at 1 year, were compared in
patients treated with the ﬁrst-generation DES (Cypher, Taxus and Endeavor-
Sprint; n¼609) versus second-generation DES (Xience V, Endeavor-Resolute and
Nobori; n¼413).
Results: Baseline characteristics were similar between patients treated with the ﬁrst-
and the second-generation DES except history of MI which was more prevalent in the
second-generation DES group than in the ﬁrst-generation DES group (6.1% vs. 2.0%,
p¼0.001). The cumulative incidence of MACE rate was 6.4% for the ﬁrst-generation
DES group and 1.2% for the second-generation DES group at 1-year follow-up
(p<0.001, Figure). One-year recurrent MI and TLR rate were signiﬁcantly lower in
the second-generation DES group than those in the ﬁrst-generation DES (0.2% vs.
2.0%, p¼0.016; 0.2% vs. 2.8%, p¼0.002, respectively). However, cardiac death rate
was not signiﬁcantly different in the both group (0.7% vs. 1.6%, p-0.261). There was a
trend towards a lower rate of stent thrombosis (deﬁnite or probable) in patients treated
with the second-generation DES compared to the ﬁrst-generation DES (1.6% vs.
0.2%, p¼0.058).
Conclusion: As compared with the ﬁrst-generation DES, the use of the second-gen-
eration DES in patients with STEMI undergoing PCI showed lower rates of MACE,
recurrent MI and TLR at 1 year. There was a trend towards a lower rate of stent
thrombosis with the second-generation DES compared to the ﬁrst-generation DES.L/Acute Coronary Syndrome: STEMI, NSTE-ACS S5
